PRESS RELEASE published on 09/19/2021 at 17:30 from SANOFI-AVENTIS ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC